Profile Response Detail

Molecular Profile SMO F460L
Therapy Vismodegib
Indication/Tumor Type Advanced Solid Tumor
Response Type resistant
Create By cms
Update By cms


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
SMO F460L Advanced Solid Tumor resistant Vismodegib Preclinical Actionable In a preclinical study, a transformed cell line expressing SMO F460L demonstrated resistance to Erivedge (vismodegib) as compared to wild-type (PMID: 25759020). 25759020
PubMed Id Reference Title Details
(25759020) Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Full reference...